Rallybio Reports Results From Phase 1 Confirmatory PK/PD Clinical Trial Evaluating RLYB116 In Development For Patients With Complement-Mediated Diseases With Initial Focus On Immune PTR And Refractory APS

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases –

– Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topline Data in 2027 –

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediated diseases with its initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS).